The combination of anti-inflammatory drugs (which are current treatments for MS) with therapies aiming at inhibiting Sema3A signaling in order to repair myelin and enhancing neuronal plasticity would be an interesting strategy toward a regenerative treatment for MS. This evidence concerns the gene SEMA3A and myeloid sarcoma.